TORONTO, ONTARIO: On track to report clinical data from TTI-621 program at the end of 2016 IND submitted to initiate a Phase 1 trial with TTI-621 in solid tumors Cash amounted to $60.1 million (CDN) as of June 30, 2016 ...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.